Volumina Medical

What Volumina Medical does

Volumina Medical SA is a Swiss clinical-stage MedTech company founded in 2018 as a spin-off from EPFL research, headquartered at Biopôle in Epalinges within Switzerland's Health Valley. The company develops the AdiPearl platform — an injectable, porous polysaccharide-based scaffold designed to enable scaffold-guided adipogenesis, in which the body's own stem cells migrate into the engineered micropore architecture, form new blood vessels, and develop vascularized adipose tissue while the scaffold itself gradually resorbs. The technology is positioned as a fundamentally new category in aesthetic and reconstructive medicine, distinct from conventional dermal fillers (temporary volume, foreign materials), biostimulators (inflammatory response), and surgical fat transfer (invasive, unpredictable outcomes), with applications spanning facial and body aesthetic volumization as well as reconstructive use cases such as breast reconstruction following cancer surgery.

AdiPearl is supplied as a 1 mL prefilled syringe for minimally invasive delivery via needle or cannula, with no surgical facility required, room-temperature stability, and an immediate volumizing effect that transitions into living tissue as the scaffold resorbs. Manufacturing is conducted under ISO 13485 and Medical Device Regulation (MDR) standards. The company has no customers, no disclosed revenue, and AdiPearl remains an investigational product not yet commercially available; pricing is not publicly disclosed. The business model will ultimately be product sales of an approved medical device, with current go-to-market activity focused on clinical partnerships with leading hospitals and KOLs in regenerative medicine across Switzerland, Germany, and Sweden, alongside scientific publications, investigator meetings, and physician early-access programs. A hybrid segmentation approach targets aesthetic and reconstructive surgeons, dermatologists, and patients with soft-tissue loss as primary end users.

Name

Volumina Medical

Legal name

Volumina Medical SA

Website

https://volumina-medical.ch

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

Volumina Medical is a Swiss clinical-stage MedTech company developing AdiPearl, an injectable polysaccharide scaffold that enables scaffold-guided regeneration of living adipose tissue for aesthetic and reconstructive soft-tissue applications, currently in pre-commercial clinical trials across Switzerland, Germany, and Sweden.

Ownership category

akta.pro rank

Product category

Regenerative Medicine Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113)

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials) (HLAAAGAB)

akta.pro secondary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

Keywords

• Soft tissue regeneration
• Injectable scaffolds
• Regenerative medicine
• Biomaterial implants
• Dermal fillers

Headquarters

HQ city

Epalinges

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Others

Revenue model

1. AdiPearl® Dermal Filler: Volumina Medical is developing its lead product AdiPearl®, an injectable dermal filler for tissue regeneration. The company is in pre-commercial stage with clinical trials ongoing. Revenue will be generated through product sales once regulatory approval is obtained in international markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Volumina Medical develops the AdiPearl® Platform, an injectable scaffold-based biomaterial technology for soft-tissue regeneration. Its lead product AdiPearl® is a porous, biocompatible polysaccharide scaffold delivered via 1 mL prefilled syringe through needle or cannula that guides the body's own stem cells to form new, vascularized adipose tissue. The scaffold gradually resorbs and is replaced by living tissue, addressing aesthetic and reconstructive applications including breast reconstruction after cancer surgery.

Product overview

Volumina Medical offers the AdiPearl® Platform as its primary technology — a scaffold-guided tissue regeneration system designed for soft-tissue restoration. The core AdiPearl® product is an injectable scaffold made from biocompatible natural polysaccharides that supports the body's own cells in regenerating living adipose tissue. Delivered via a 1 mL prefilled syringe through needle or cannula injection, the technology addresses both aesthetic and reconstructive applications including breast reconstruction post-cancer surgery. The scaffold resorbs over time, leaving behind vascularized, living tissue rather than temporary volume. The company is developing platform extensions to support regeneration across a broader range of tissues.

Differentiator

Problem solved

Functional benefit

Brands

• AdiPearl® Platform: Scaffold-guided tissue regeneration platform for soft tissue volume restoration using biocompatible polysaccharides.

Products and services

• AdiPearl® Platform A scaffold-guided tissue regeneration platform composed of highly porous, biocompatible polysaccharides engineered to gradually resorb and be replaced by the patient's own regenerated tissue. Designed for stem cell integration and vascularized adipose tissue formation for soft-tissue volume restoration in face and body applications.
• AdiPearl® An injectable dermal filler and scaffold product for soft-tissue regeneration supplied in a 1 mL prefilled syringe for delivery via needle or cannula. Guides the body's own stem cells to form young, vascularized adipose tissue and is intended for aesthetic and reconstructive indications including breast reconstruction after cancer surgery.

Quantifiable outcome

• AdiPearl® is designed to regenerate adipose tissue by replacing lost volume with living tissue rather than filling space
• +1 more outcomes

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered core.

• EPFL (École Polytechnique Fédérale de Lausanne)coreStrategic or Co-development PartnerAcademic research partner and company origin. Volumina Medical was founded based on pioneering research at EPFL. The company's AdiPearl technology is born from Swiss science and EPFL research. Located in Lausanne close to EPFL campus.
• BiopôlecoreStrategic or Co-development PartnerHost institution and life sciences campus in Epalinges, Switzerland. Company headquarters located at Biopôle campus, part of Switzerland's Health Valley ecosystem.
• Clinical Partners (Leading Hospitals and Clinics)coreStrategic or Co-development PartnerLeading hospitals and clinics validating AdiPearl solutions in real-world clinical settings. Clinical partners conducting investigations in Germany, Sweden, and Switzerland under key opinion leaders in regenerative medicine.
• Academic Partners (Universities and Research Institutions)coreStrategic or Co-development PartnerCollaborating universities and research institutions driving scientific discovery and innovation. Partners contribute to peer-reviewed publications and advancing regenerative medicine research.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• AbbVie (Allergan Aesthetics): Owns Juvéderm (HA filler), CoolSculpting, and the breast implant portfolio from Allergan. Defines the incumbent benchmark for both injectable aesthetics and breast reconstruction, with unmatched commercial reach that any new soft-tissue entrant must contend with.
• Galderma: Global aesthetics leader with Sculptra (PLLA biostimulator) and Restylane (HA filler) directly competing for the same physician customers and patient indications Volumina targets. Sets the standard Volumina must displace in dermatology and plastic surgery channels.
• Integra LifeSciences: Public regenerative tissue company with collagen and dermal matrix products used in reconstruction and wound care. Comparable scaffold-and-matrix business model and overlap in soft-tissue reconstruction indications.
• Merz Aesthetics: Sells Radiesse (CaHA biostimulator) and Belotero (HA filler), plus Ultherapy. Competes head-to-head with Volumina in aesthetic volume restoration and increasingly in regenerative/biostimulator positioning.
• Organogenesis: Public regenerative medicine company with skin substitutes (Apligraf, Dermagraft) and surgical biologics. Comparable in delivering living-tissue and scaffold-based products through surgical and wound-care channels in regulated markets.

Emerging players

• PolarityTE: Small US regenerative medicine company developing autologous tissue platforms (SkinTE, etc.) for soft-tissue and wound applications. Comparable in trying to deliver living tissue rather than inert filler, though uses a different biological mechanism.
• Cytori Therapeutics / Bimini Technologies: Developed cell-based adipose-derived regenerative technologies (Celution system) for soft-tissue and aesthetic indications. Closest historic peer in attempting regenerative adipose tissue for aesthetic and reconstructive use, even though their mechanism is cell-based rather than scaffold-based.
• Tissue Regenix (Cartessa): Develops dCELL and BioRinse scaffold-based products for soft-tissue and orthopedic regeneration. Smaller emerging player with similar scaffold-architecture technology in adjacent soft-tissue indications.

Direct peers

• CollPlant Biotechnologies: Israel/US regenerative medicine company developing plant-derived recombinant collagen scaffolds for soft tissue and breast indications. Directly comparable technology category (biomaterial scaffold) and overlapping aesthetic/reconstructive use cases.
• Establishment Labs: Public aesthetics and breast reconstruction company developing Motiva implants and a regenerative tissue platform (Puregraft, etc.). Most direct comparable because it overlaps on breast reconstruction focus and is investing in regenerative soft-tissue technology rather than just static implants.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/VoluminaMedical
• LinkedInlinkedin.com/company/voluminamedical

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds11 records

Investors8 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Volumina Medical